Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

ODI Pharma

1.60 SEK

+8.11 %

Less than 1K followers

ODI

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+8.11 %
+21.21 %
+3.23 %
-20.79 %
-27.93 %
-44.06 %
-59.52 %
-69.75 %
-85.75 %

ODI Pharma is a producer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are made through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. Operations are found within the European market, with the headquarters in Stockholm.

Read more
Market cap
29.33M SEK
Turnover
16.19K SEK
Revenue
3.11M
EBIT %
-168.49 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.12
2025

General meeting '25

26.2
2026

Interim report Q2'26

28.5
2026

Interim report Q3'26

All
Press releases
ShowingAll content types
Press release11/27/2025, 3:35 PM

ODI Pharma: Publication of interim report Q1 2025/2026

ODI Pharma
Press release11/24/2025, 2:15 PM

ODI Pharma demonstrates clear operational progress and improved commercial outlook

ODI Pharma
Press release11/21/2025, 6:00 PM

ODI Pharma AB publishes the annual report for the fiscal year 2024/2025

ODI Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10/31/2025, 11:10 AM

Notice to Annual General Meeting in ODI Pharma AB (publ)

ODI Pharma
Press release8/29/2025, 9:22 AM

ODI Pharma publishes financial calendar for 2025

ODI Pharma
Press release8/28/2025, 4:10 PM

ODI Pharma: Publication of year-end report Q4 2024/2025

ODI Pharma
Press release6/26/2025, 1:55 PM

ODI Pharma: Report from the Extraordinary General Meeting

ODI Pharma
Regulatory press release6/9/2025, 6:15 PM

ODI Pharma proposes directed share issue of approximately SEK 2.0 million

ODI Pharma
Press release5/29/2025, 12:00 PM

ODI Pharma: Publication of interim report Q3 2024/2025

ODI Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.